Date Title
September 17, 2018
Realm Therapeutics Provides Corporate Update and Hires Advisor to Support Strategic Review including Formal Sale Process

MALVERN, Pa. , Sept. 17, 2018 /PRNewswire/ --  Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration hypochlorous acid (HOCl), today provides a corporate update following the August 14, 2018 announcement

August 14, 2018
Realm Therapeutics Reports Top-line Data from Phase 2 Trial of PR022 in Atopic Dermatitis and First Half 2018 Financial Results

Company Hosting Conference Call Today at 9:00 AM ET / 2:00 PM BST MALVERN, Pa. , Aug. 14, 2018 /PRNewswire/ --  Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today reports preliminary

August 8, 2018
Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

MALVERN, Pa. , Aug. 8, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announces today that Alex Martin, CEO, will be presenting at the 2018 Wedbush PacGrow

August 7, 2018
Realm Therapeutics to Report First Half 2018 Financial Results

MALVERN, Pa. , Aug. 7, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company will report its first half 2018 financial results on

July 10, 2018
Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis

MALVERN, Pa. , July 10, 2018  /PRNewswire/ -- Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces the publication of a pre-clinical study demonstrating comparable activity

July 4, 2018
Realm Therapeutics Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq listed ADSs

MALVERN, Pa.   , July 4, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM; Nasdaq: RLM) (the "Company"), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today separately announced that in connection with a listing of American

July 4, 2018
Realm Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares

MALVERN, Pa. , July 4, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM; Nasdaq: RLM) (the "Company") a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that in connection with a listing of American Depositary Shares

July 4, 2018
Realm Therapeutics - Instructions for Exchanging Ordinary Shares

RNS Number : 5070T Realm Therapeutics PLC 03 July 2018   Realm Therapeutics Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq listed ADSs   MALVERN, PA July 4, 2018 - Realm Therapeutics plc (AIM: RLM; Nasdaq: RLM) (the "Company"), a clinical stage biopharmaceutical company

June 14, 2018
Realm Therapeutics Announces Results of 2018 Annual General Meeting

MALVERN, Pa. , June 14, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that all Resolutions put to shareholders were duly passed at its Annual General Meeting

May 31, 2018
Realm Therapeutics to Present at June Investor Conferences

MALVERN, Pa. , May 31, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company will participate in the following investor conferences in June: The 2018

Displaying 1 - 10 of 19

Search Investor Relations